So far, two phase II clinical trials on the effectiveness of anti-PD-1/PD-L1 inhibitors in patients with advanced germ cell tumors have been completed [39, 40], two phase II trials were terminated [41, 42], while there are one phase I [43] and five phase II [44–48] ongoing clinical trials. This evidence concerns the gene CD274 and germ cell tumor.